Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review.
Dyne Therapeutics
Dyne Therapeutics (NASDAQ: DYN) is a clinical-stage muscle disease company developing targeted therapeutics for genetically driven muscle disorders including Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). Its FORCE platform delivers oligonucleotides to muscle tissue.
Company Info
Sector:RNA Therapeutics / Genetic Medicine
Headquarters:Waltham, Massachusetts, USA
Founded:2018
Website:www.dyne-tx.com/
Recent News
Leadership Team
Careers & Job Openings